Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy

Jia Wei; Zekai Mao; Na Wang; Lifang Huang; Yang Cao; Weimin Sun; Xiaolu Long; Jiaqi Tan; Chunrui Li; Yi Xiao; Chaojiang Gu; Shangkun Zhang; Yicheng Zhang; Tongcun Zhang; Jianfeng Zhou; Liang Huang

doi:10.1002/ctm2.176

Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy

Clin Transl Med. 2020 Sep;10(5):e176. doi: 10.1002/ctm2.176.

Authors

Jia Wei^{1

2}, Zekai Mao^{1

2}, Na Wang^{1

2}, Lifang Huang^{1

2}, Yang Cao^{1

2}, Weimin Sun^{1

2}, Xiaolu Long^{1

2}, Jiaqi Tan^{1

2}, Chunrui Li^{1

2}, Yi Xiao^{1

2}, Chaojiang Gu^{3

4}, Shangkun Zhang⁴, Yicheng Zhang^{1

2}, Tongcun Zhang^{3

4}, Jianfeng Zhou^{1

2}, Liang Huang^{1

2}

Affiliations

¹ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
² Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
³ College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, Hubei, China.
⁴ Wuhan Bio-Raid Biotechnology Co., Ltd, Wuhan, Hubei, China.

No abstract available

Publication types

Letter